Overview
Location
United States
Total raised
$35M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 31, 2026 | EIT Pharma Raises $35 Million Series A Led By Propel Bio Partners As Lonafarnib NDA Enters FDA Review | EIT Pharma has closed an oversubscribed $35 million Series A financing round to advance its infectious disease pipeline, including preparations surrounding the potential approval and commercialization of lonafarnib for chronic hepatitis D. ... |
| Aug 31, 2026 | Easy Aerial Raises $20M in Series B Funding | Easy Aerial, a NYC-based provider of autonomous tethered aerial intelligence and defense systems, raised $20M in Series B funding. Backers included Insight Partners, Entrée Capital, and private U.S. investors. The company intends to use the... |
| EIT Pharma | “Learn about EIT Pharma. We are committed to addressing infectious diseases with high unmet needs, because no patient should be left behind.” |
Reviews 0
FAQ about EIT Pharma
How much funding has EIT Pharma raised?
EIT Pharma has raised $35M in total across 1 funding round.
What has the press written about EIT Pharma?
Parsers VC has collected 4 articles mentioning EIT Pharma, among them “EIT Pharma Raises $35 Million Series A Led By Propel Bio Partners As Lonafarnib NDA Enters FDA Review” (Aug 31, 2026) and “Easy Aerial Raises $20M in Series B Funding” (Aug 31, 2026).
Is EIT Pharma still active?
Yes, EIT Pharma is active; its latest activity on Parsers VC dates from Aug 31, 2026.